<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744690</url>
  </required_header>
  <id_info>
    <org_study_id>15-16075-MMC</org_study_id>
    <nct_id>NCT02744690</nct_id>
  </id_info>
  <brief_title>Mitomycin C Trabeculectomy Trial for Glaucoma in Ethiopia</brief_title>
  <official_title>Topical vs Injection Application of Mitomycin C Trabeculectomy Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Menelik II Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-masked trial to examine the response to trabeculectomy&#xD;
      surgery. In this study, patients will be randomized to receive MMC via subconjunctival&#xD;
      injection or topical sponge application.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-masked (study participants and outcome assessors) trial.&#xD;
      During the enrollment period, patients from Menelik Hospital who are planning to have&#xD;
      trabeculectomy surgery and who meet the study enrollment criteria will be randomized to&#xD;
      receive mitomycin C applied topically or by injection during the surgery.At Menelik Hospital&#xD;
      mitomycin-C (MMC) is routinely applied to the eye prior to trabeculectomy by physicians via&#xD;
      both sponge and injection routes. The primary outcome is the patient's response to the&#xD;
      trabeculectomy procedure, as measured by cumulative complications after a 3-month follow-up&#xD;
      period post-operation. Secondary outcome is the change in intraocular pressure after a 3&#xD;
      month follow-up period. The investigators will perform subgroup analyses by stratifying the&#xD;
      population according to skin pigmentation to determine whether pigmentation is a predictor of&#xD;
      treatment success.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of complications</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>Comparison of the cumulative incidence of complications between the treatment groups (MMC sponge and injection application) 3 months after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of complications</measure>
    <time_frame>6 and 12 months after surgery</time_frame>
    <description>Comparison of the cumulative incidence of complications between the treatment groups (sponge and injection application of MMC) 6 months and 12 months after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of intraocular pressure from baseline, mmHg</measure>
    <time_frame>3, 6, and 12 months after surgery</time_frame>
    <description>The investigators will compare the reduction of IOP from baseline between the treatment groups at 3, 6, and 12 months after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>MMC Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: At the intended surgical site and about 6mm from the limbus, 0.2ml of 0.2mg/ml of mitomycin-C (MMC) will be injected subconjunctivally before peritomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMC Sponge Application</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: After peritomy, three half-sponges soaked in 0.2mg/ml mitomycin-C (MMC) will be placed posterior to the area of intended filtration. After 2 minutes, the sponges will be removed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin-C (MMC)</intervention_name>
    <description>Mitomycin-C is routinely applied to the eye prior to trabeculectomy at Menelik II Hospital</description>
    <arm_group_label>MMC Injection</arm_group_label>
    <arm_group_label>MMC Sponge Application</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;=40&#xD;
&#xD;
          -  Planning to have a trabeculectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life threatening or debilitating disease&#xD;
&#xD;
          -  Inability to complete necessary exams and/or ocular disease that would preclude&#xD;
             assessment of intraocular pressure, visual field, or optic disc&#xD;
&#xD;
          -  Pseudophakic lens&#xD;
&#xD;
          -  Contralateral eye already enrolled in study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy D Keenan, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeremy D Keenan, MD, MPH</last_name>
    <phone>415-476-6323</phone>
    <email>Jeremy.Keenan@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caitlin A Moe, MS</last_name>
    <phone>415-502-2665</phone>
    <email>Caitlin.Moe@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Menelik II Hospital</name>
      <address>
        <city>Addis Ababa</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abiy Mulugeta, MD</last_name>
      <phone>2511911407925</phone>
      <email>abmulugeta@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Abeba T Giorgis, MD</last_name>
      <email>abebatgiorgis@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Abeba T Giorgis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abiy Mulugeta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ethiopia</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Jeremy Keenan</investigator_full_name>
    <investigator_title>Associate Professor/Director International Programs</investigator_title>
  </responsible_party>
  <keyword>Eye Disease</keyword>
  <keyword>Intraocular Pressure</keyword>
  <keyword>Visual Acuity</keyword>
  <keyword>Trabeculectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

